Author: Zhiguo Wang

MicroRNAs and Cardiovascular Disease

eBook: US $59 Special Offer (PDF + Printed Copy): US $136
Printed Copy: US $107
Library License: US $236
ISBN: 978-1-60805-332-2 (Print)
ISBN: 978-1-60805-184-7 (Online)
Year of Publication: 2010
DOI: 10.2174/97816080518471100101


Micro RNAs (miRNAs) are known to play an important role in gene expression regulation. Owing to their ever-increasing implications in the control of various biological and pathological processes, miRNAs have now been considered novel biomarkers of various human diseases including, cancer, viral disease, cardiovascular disorders, metabolic disturbances, etc. Unique expression profiles have been associated with specific pathological states.

Cardiovascular disease is among the main causes of mortality in developed countries. The pathological process of the heart is associated with altered expression profile of genes that are important for cardiac function. The implications of miRNAs in the pathological process of the cardiovascular system have recently been recognized, and the research on miRNAs in relation to cardiovascular disease is now in rapid progress. The aim of this ebook is to present updated research on the subject with analyses from published reports. Micro RNAs and Cardiovascular Disease caters to the growing interest and information needs of cardiac clinicians and gene expression researchers.

Indexed in: Book Citation Index, Science Edition, BIOSIS Previews, Scopus, EBSCO.


Cardiovascular disease remains the major cause of morbidity and mortality; according to statistics, heart failure, the syndrome consequential to many diseases of the cardiovascular system, is estimated to have a prevalence of 1–2% and an annual incidence of 5–10 per 1,000 in the developed countries and is the leading cause of hospitalization in the population over 50 years of age. Worse so, there is a clear tendency of increasing prevalence of cardiovascular disease in this planet particularly in the developing nations. This problem casts enormous health concern and costly socioeconomic burden worldwide. Improving our understanding in depth of cardiac pathophysiology and translating our updated knowledge into the clinical practice through the innovation of novel diagnostics and therapeutics has become the most urgent task of scientists and health professionals.

We have entered post-genome era after the human genome project had been completed years ago. Only <2% of all transcribed bases of the entire human genome constitutes the genetic sequence encoding proteins and the rest of 98% accounting for ~70% of all genes carry the sequences for RNAs not encoding a polypeptide chain that was used to be considered for many years “junk DNA” of no physiologic function; proteins were generally assumed the sole biopolymer capable of regulatory function. Intriguingly, the proportion of transcribed non-protein-coding sequences increases with developmental complexity and is a better indicator of phylogenetic level than the number of proteincoding genes of an organism. It is now known that “junk DNA” encodes non-protein-coding RNAs (ncRNAs) that are involved in determining the expression of protein-coding genes by regulating the activity of that 2% of the genome. These ncRNAs include microRNAs (miRNAs), once ignored completely or overlooked as cellular detritus, which were discovered over a decade ago have recently taken many by surprise because of their widespread expression and diverse functions. The discovery of miRNAs challenges the central dogma of molecular biology that has be held since the latter half of the 20th century. This central tenet teaches the flow of genetic information: ribonucleotiac acid (RNA) functions either as infrastructure (a role performed by housekeeping species of RNA) or merely as an intermediate from the deoxynucleotide sequence of genomic DNA through the transcription process, housed within the nucleus, to the amino acid sequence of proteins, which are synthesized in the cytoplasm by the translation process. It has been firmly established that miRNAs play a central role in regulating the expression of protein-coding genes by translational repression at the post-transcriptional level. Since their discovery in 1993, the importance of miRNAs has steadily gained appreciation and now miRNA biology has exploded into a massive swell of interests with enormous range and potential in almost every biological discipline.

microRNAs and Cardiovascular Disease aims to target a wide range of readers from graduate students to postdoctoral fellow and senior researchers involving cardiovascular and miRNA research fields in universities, research institutions, and pharmaceuticals. The contents of the book are also suitable for cardiologists and other health professionals, who are interested in updating their knowledge and utilizing miRNAs as a complementary and an alternative strategy for clinical diagnosis and therapy of human cardiac disease. It provides the most updated information on miRNAs in the cardiovascular system based on the literature available, along with focused highlight, detailed reanalysis, unbiased commentary, and rational speculation. The book is divided into five sections that contain a total of 18 chapters. The book begins with Section I introducing the basics of miRNAs and expression profiles of miRNAs in the cardiovascular system. From Section II to Section IV, each of the 14 chapters is focused on the role of miRNAs in an independent entity of cardiovascular function or disease. Each single chapter contains three subsections: introduction, main body, and reference. In addition, wherever appropriate, illustrations, flow charts or tables for easier and straightforward understanding of the contents are presented.

Zhiguo Wang
University of Montreal


.Pharmacotherapeutic Management of Cardiovascular Disease Complications: A Textbook for Medical Students.
.Perinatal Cardiology-Part 1.
.Perinatal Cardiology-Part 2.
.4D Fetal Echocardiography.
.New Trends in Biomarkers and Diseases Research: An Overview.